Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

Cagatay, Tülin; Bingol, Züleyha; Kiyan, Esen; Yegin, Zeynep; Okumus, Nigar; Arseven, Orhan; Erkan, Feyza; Gulbaran, Ziya; Erelel, Mustafa; Ece, Turhan; Cagatay, Penbe; Kilicaslan, Zeki

doi:10.1111/crj.12726

Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk

Cagatay T., Bingol Z., Kiyan E., Yegin Z., Okumus G., Arseven O., ...Daha Fazla

CLINICAL RESPIRATORY JOURNAL, cilt.12, sa.4, ss.1668-1675, 2018 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 12 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1111/crj.12726
Dergi Adı: CLINICAL RESPIRATORY JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1668-1675
Anahtar Kelimeler: adalimumab, etanercept, infliximab, Mycobacterium tuberculosis, nontuberculosis mycobacterium, tumor necrozing factor alpha antagonists, RHEUMATOLOGY-BIOLOGICS-REGISTER, ANTI-TNF THERAPY, BRITISH-SOCIETY, ARTHRITIS, MYCOBACTERIAL, INFLIXIMAB, DISEASES, INFECTIONS
İstanbul Üniversitesi Adresli: Evet

Özet

ObjectivesTo evaluate the characteristics of patients who developed tuberculosis while receiving tumor necrosis factor-alpha (TNF-) antagonists and the related factors with tuberculosis.